Alumis Inc. ALMS 深 沪
交易中 05-11 10:54:40 美东时间
24.84
+1.190
+5.03%
华盛通- 最 高26.50
- 今 开23.70
- 成交量 28.79万股
- 最 低 23.44
- 昨 收 23.65
- 总市值 0
- 52周最高 30.60
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 2.7601
- 委 比 94.87%
- 总股本 --
- 历史最高 30.60
- 量 比 2.00
- 振 幅 12.94%
- 历史最低 2.7601
- 每 手 1
- 风险率 9.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7
The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise.
01-16 05:12
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars
Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and favorable safety, while beating a rival treatment.
01-06 23:47
US Stocks Mixed; Nasdaq Gains Over 50 Points
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining more t...
01-06 22:49
Alumis to Present at the Jefferies Global Healthcare Investor Conference
Alumis Inc.'s CEO, Martin Babler, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET. A live webcast will be available on the company's website, along with a 90-day replay. Alumis focuses on developing next-generation targeted therapies for immune-mediated diseases.
2025-05-29 20:15
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
Alumis Inc. announced the completion of patient enrollment in its Phase 3 ONWARD clinical program for ESK-001, a potential treatment for moderate-to-severe plaque psoriasis. Over 1,700 patients were enrolled, with topline results expected in early Q1 2026.
2025-05-29 11:55
Alumis Completes Merger with ACELYRIN
Alumis Inc. completes merger with ACELYRIN Inc., offering 0.4814 Alumis shares per ACELYRIN share. ACELYRIN stock ceases trading. The merger strengthens Alumis' balance sheet, enabling advancement of its late-stage pipeline through 2027.
2025-05-21 13:10
Reported Saturday, Alumis' ESK-001 Demonstrates Sustained PASI 90 And PASI 100 Responses At Week 52 In Phase 2 Psoriasis Study
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupusPhase 2 OLE data of ESK-001 at 40 mg BID
2025-03-10 15:43
Samsara Biocapital LP Reports 6.9% Stake In Alumis As Of July 1
Samsara Biocapital LP Reports 6.9% Stake In Alumis As Of July 1
2024-08-28 04:30
